London Daily

Focus on the big picture.
Wednesday, Jul 30, 2025

Galleri cancer test: What is it and who can get it?

Galleri cancer test: What is it and who can get it?

Tens of thousands of volunteers are being recruited in a trial of a potentially "game-changing" blood test for cancer.

It's hoped the Galleri test can detect more than 50 types of the disease before symptoms appear.

What is the Galleri cancer test?


It's a simple blood test that looks for the earliest signs of cancer, particularly those that are typically difficult to identify early or for which there are no NHS screening programmes - such as lung, pancreas or stomach cancers.

Developed by Californian firm Grail - and already used in the US - the test can detect subtle changes caused by cancers, when patients may have no other obvious symptoms.

It works by finding chemical changes in fragments of genetic code - cell-free DNA (cfDNA) - that leak from tumours into the bloodstream.

The signal does not mean that a person definitely has cancer. It just means that they might have cancer, and that they will need to have some follow-up tests to check.

"This quick and simple blood test could mark the beginning of a revolution in cancer detection and treatment here and around the world," says NHS England's Chief Executive Amanda Pritchard.

How will the trial work?


Participants will be asked to give a blood sample at a locally based mobile clinic.

They will then be invited back twice - after 12 months and two years - to give further samples.

Half those taking part will have their blood screened with the Galleri test immediately.

However, others will simply have their samples stored away to be tested in the future - should they go on to be diagnosed with cancer.

This is because the trial is what's known as a Randomised Control Trial (RCT).

It will allow scientists to see whether cancer is detected significantly earlier among people who have their blood tested straight away.

Will participants know if their blood has been tested?


People will only know they're in the first test group if they are among the small minority whose blood test detects potential signs of cancer.

Those people will be contacted by the trial nurses by phone and referred to an NHS hospital for further tests.

Everyone taking part will be advised to continue with their standard NHS screening appointments and to still contact their GP if they notice any new or unusual symptoms.

Who can volunteer for the NHS-Galleri trial?


The trial aims to recruit 140,000 volunteers across England.

But only people living in these areas can take part and they must be invited:

*  Cheshire and Merseyside
*  Cumbria
*  Greater Manchester
*  the North East
*  West Midlands
*  East Midlands
*  East of England
*  Kent and Medway
*  South East London

Letters have already been sent to tens of thousands of people asking them to take part.

Those being asked are aged between 50 and 77, from a range of backgrounds and ethnicities, and must not have had a cancer diagnosis in the past three years.

What is the aim of the trial?


The NHS hopes the blood tests will help increase five-year survival rates for cancer, which are below the levels seen in many other high-income countries.

Developing a blood test for cancer has been keeping scientists busy for many years without much success.


Making one that's accurate and reliable has proved incredibly complex. The danger is that a test doesn't detect a person's cancer when they do have it, or it indicates someone has cancer when they don't.

"The test could be a game-changer for early cancer detection," says Prof Peter Sasieni, one of the trial's lead investigators. But he adds a note of caution:

"Cancer screening can find cancers earlier when they are more likely to be treated successfully, but not all types of screening work."

What difference could it make to cancer patients?


Patients whose cancers are found early - known as stage one or two - typically have a broader range of treatment options available to them, which can often be less aggressive.


NHS England says a patient diagnosed at the earliest stage typically has between five and 10 times the chance of surviving compared with those found at the more advanced stage four.

Initial results from the Galleri study are expected by 2023. If successful, the NHS in England plans to extend the rollout to a further one million people in 2024 and 2025.

Newsletter

Related Articles

0:00
0:00
Close
Former Judge Charged After Drunk Driving Crash Kills Comedian in Brazil
Jeff Bezos hasn’t paid a dollar in taxes for decades. He makes billions and pays $0 in taxes, LEGALLY
China Increases Use of Exit Bans Amid Rising U.S. Tensions
IMF Upgrades Global Growth Forecast as Weaker Dollar Supports Outlook
Procter & Gamble to Raise U.S. Prices to Offset One‑Billion‑Dollar Tariff Cost
House Republicans Move to Defund OECD Over Global Tax Dispute
Botswana Seeks Controlling Stake in De Beers as Anglo American Prepares Exit
Trump Administration Proposes Repeal of Obama‑Era Endangerment Finding, Dismantling Regulatory Basis for CO₂ Emissions Limits
France Opens Criminal Investigation into X Over Algorithm Manipulation Allegations
A family has been arrested in the UK for displaying the British flag
Mel Gibson refuses to work with Robert De Niro, saying, "Keep that woke clown away from me."
Trump Steamrolls EU in Landmark Trade Win: US–EU Trade Deal Imposes 15% Tariff on European Imports
ChatGPT CEO Sam Altman says people share personal info with ChatGPT but don’t know chats can be used as court evidence in legal cases.
The British propaganda channel BBC News lies again.
Deputy attorney general's second day of meeting with Ghislaine Maxwell has concluded
Controversial March in Switzerland Features Men Dressed in Nazi Uniforms
Politics is a good business: Barack Obama’s Reported Net Worth Growth, 1990–2025
Thai Civilian Death Toll Rises to 12 in Cambodian Cross-Border Attacks
TSUNAMI: Trump Just Crossed the Rubicon—And There’s No Turning Back
Over 120 Criminal Cases Dismissed in Boston Amid Public Defender Shortage
UN's Top Court Declares Environmental Protection a Legal Obligation Under International Law
"Crazy Thing": OpenAI's Sam Altman Warns Of AI Voice Fraud Crisis In Banking
The Podcaster Who Accidentally Revealed He Earns Over $10 Million a Year
Trump Announces $550 Billion Japanese Investment and New Trade Agreements with Indonesia and the Philippines
US Treasury Secretary Calls for Institutional Review of Federal Reserve Amid AI‑Driven Growth Expectations
UK Government Considers Dropping Demand for Apple Encryption Backdoor
Severe Flooding in South Korea Claims Lives Amid Ongoing Rescue Operations
Japanese Man Discovers Family Connection Through DNA Testing After Decades of Separation
Russia Signals Openness to Ukraine Peace Talks Amid Escalating Drone Warfare
Switzerland Implements Ban on Mammography Screening
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
×